• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings

    7/24/24 2:37:16 PM ET
    $AZTR
    $LW
    $NUWE
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Packaged Foods
    Consumer Staples
    Get the next $AZTR alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 100 points on Wednesday.

    The Dow traded down 0.82% to 40,025.48 while the NASDAQ fell 2.92% to 17,472.06. The S&P 500 also fell, dropping, 1.84% to 5,453.67.

    Check This Out: Jim Cramer Calls Axsome A ‘Double Or Nothing Stock,’ Says SAP Is ‘Incredible’

    Leading and Lagging Sectors

    Utilities shares jumped by 0.8% on Wednesday.

    In trading on Wednesday, consumer discretionary shares fell by 3%.

    Top Headline

    Shares of AT&T Inc. (NYSE:T) rose around 5% during Wednesday’s session following second-quarter earnings.

    AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down 0.4% year over year and missing the analyst consensus estimate of $29.9 billion. Adjusted EPS of 57 cents is in line with the analyst consensus estimate, according to data from Benzinga Pro.

    Equities Trading UP
                           

    • Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) shares shot up 78% to $14.15 after the company announced that the company entered into a definitive merger agreement with Palvella Therapeutics.
    • Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) got a boost, surging 47% to $0.5914 after licensing partner Pfizer’s Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec met its primary endpoint.
    • PROG Holdings, Inc. (NYSE:PRG) shares were also up, gaining 21% to $42.02 after the company reported better-than-expected second-quarter financial results. Also, the company raised its FY24 guidance above estimates.

    Equities Trading DOWN

    • Azitra, Inc. (NYSE:AZTR) shares dropped 76% to $1.1899 after the company announced the pricing of a $10 million public offering of 6,665,000 common shares and Class A warrants at $1.50 per share.
    • Shares of Nuwellis, Inc. (NASDAQ:NUWE) were down 40% to $2.49 after the company announced the pricing of a $2 million public offering of 469,340 common shares at $4.24 a share.
    • Lamb Weston Holdings, Inc. (NYSE:LW) was down, falling 28% to $56.37 after the company reported worse-than-expected quarterly financial results. Also, the company issued its FY25 EPS guidance below estimates.

    Also Check This Out: Top 3 Tech And Telecom Stocks That Are Set To Fly In July

    Commodities

    In commodity news, oil traded up 1% to $77.72 while gold traded up 0.4% at $2,417.40.

    Silver traded up 0.1% to $29.35 on Wednesday, while copper fell 1.2% to $4.1110.

    Euro zone

    European shares closed lower today. The eurozone's STOXX 600 fell 0.61%, Germany's DAX fell 0.92% and France's CAC 40 fell 1.12%. Spain's IBEX 35 Index fell 0.02%, while London's FTSE 100 fell 0.17%.

    The HCOB Eurozone manufacturing PMI declined to 45.6 in July from 45.8 in June, while services PMI slipped to 51.9 from 52.8. The HCOB France composite PMI climbed to 49.5 in July from 48.8 in the prior month, while German composite PMI declined to 48.7 from 50.4.

    The S&P Global Flash UK manufacturing PMI rose to 51.8 in July from 50.9 in June, while services PMI rose to 52.4 in July from 52.1 in the previous month.

    Asia Pacific Markets

    Asian markets closed lower on Wednesday, with Japan's Nikkei 225 falling 1.11%, Hong Kong's Hang Seng Index falling 0.91%, China's Shanghai Composite Index declining 0.46% and India's S&P BSE Sensex declining 0.35%.

    The HSBC India Manufacturing PMI climbed to 58.5 in July from 58.3 the prior month, while services PMI rose to 61.1 in July from 60.5. The au Jibun Bank Flash Japan composite PMI rose to 52.6 in July versus a final reading of 49.7 in June.

    Economics

    • U.S. mortgage applications declined by 2.2% in the latest week, compared to a 3.9% gain in the prior period.
    • The S&P Global flash manufacturing PMI fell to 49.5 in July from 51.6 in June and compared to market estimates of 51.7.
    • The S&P Global composite PMI climbed to 55.0 in July from 54.8 in the prior month.
    • The U.S. trade deficit in goods shrank to $96.84 billion in June versus a $99.37 billion gap in the earlier month.
    • Building permits increased by 3.9% to an annual rate of 1.454 million in June.
    • U.S. new home sales declined 0.6% month-over-month to an annualized rate of 617,000 in June.
    • The EIA said crude oil inventories in the U.S. declined by 3.741 million barrels in the week ended July 19, compared to market estimates of a 2.05 million decline.

    Now Read This: Tesla To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday

    Get the next $AZTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTR
    $LW
    $NUWE
    $PIRS

    CompanyDatePrice TargetRatingAnalyst
    AT&T Inc.
    $T
    3/11/2026$29.00 → $32.00Outperform
    Oppenheimer
    AT&T Inc.
    $T
    3/10/2026$28.00Sell → Neutral
    Arete
    AT&T Inc.
    $T
    1/6/2026$20.00Neutral → Sell
    Arete
    Lamb Weston Holdings Inc.
    $LW
    12/22/2025Outperform → Neutral
    BNP Paribas Exane
    PROG Holdings Inc.
    $PRG
    12/16/2025$50.00Buy
    B. Riley Securities
    AT&T Inc.
    $T
    12/15/2025Outperform → Peer Perform
    Wolfe Research
    PROG Holdings Inc.
    $PRG
    11/21/2025$31.00Sell → Neutral
    BTIG Research
    AT&T Inc.
    $T
    11/12/2025$30.00Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $AZTR
    $LW
    $NUWE
    $PIRS
    SEC Filings

    View All

    Nuwellis Inc. filed SEC Form 8-K: Other Events

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/17/26 9:13:10 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Azitra Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    3/13/26 5:26:35 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by AT&T Inc.

    PRE 14A - AT&T INC. (0000732717) (Filer)

    3/13/26 4:06:41 PM ET
    $T
    Telecommunications Equipment
    Telecommunications

    $AZTR
    $LW
    $NUWE
    $PIRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Emerson Martin J

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/18/26 4:26:10 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by AT&T Inc.

    4 - AT&T INC. (0000732717) (Issuer)

    3/11/26 4:24:21 PM ET
    $T
    Telecommunications Equipment
    Telecommunications

    SEC Form 4 filed by AT&T Inc.

    4 - AT&T INC. (0000732717) (Issuer)

    3/11/26 4:25:28 PM ET
    $T
    Telecommunications Equipment
    Telecommunications

    $AZTR
    $LW
    $NUWE
    $PIRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chair Craps Jan Eli B bought $2,432,330 worth of shares (50,000 units at $48.65) and was granted 317,647 shares, increasing direct ownership by 147% to 617,647 units (SEC Form 4)

    4 - Lamb Weston Holdings, Inc. (0001679273) (Issuer)

    2/6/26 5:10:07 PM ET
    $LW
    Packaged Foods
    Consumer Staples

    Chief Financial Officer Garner Brian bought $101,255 worth of shares (3,500 units at $28.93), increasing direct ownership by 3% to 132,597 units (SEC Form 4)

    4 - PROG Holdings, Inc. (0001808834) (Issuer)

    5/14/25 4:40:00 PM ET
    $PRG
    Diversified Commercial Services
    Consumer Discretionary

    President and CEO Michaels Steven A bought $435,450 worth of shares (15,000 units at $29.03), increasing direct ownership by 3% to 559,641 units (SEC Form 4)

    4 - PROG Holdings, Inc. (0001808834) (Issuer)

    5/14/25 4:39:49 PM ET
    $PRG
    Diversified Commercial Services
    Consumer Discretionary

    $AZTR
    $LW
    $NUWE
    $PIRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

    RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2025 financial results after the market closes on Monday, March 30, 2026. The company will hold a conference call at 4:30 p.m. Eastern on Monday, March 30, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participa

    3/19/26 4:03:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AT&T Launches New App to Simplify Customers' Digital Experience

    DALLAS, March 18, 2026 /CNW/ --The new AT&T app delivers fast, simple control to manage wireless and home internet services with AI-powered support and streamlined notifications. Key Takeaways:AT&T is simplifying its digital experience so customers can shop and manage all their connectivity services in one place.The new AT&T app is built around a GenAI assistant, making it faster to find what you need with a more personalized experience.We're giving customers the information, convenience and controls they deserve, with more features to come throughout the year.The News:Beginning today, AT&T is starting to roll out the new AT&T app, a simpler way to experience all of AT&T in one convenient pl

    3/18/26 7:00:00 AM ET
    $T
    Telecommunications Equipment
    Telecommunications

    Nuwellis Completes Acquisition of Rendiatech

    MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd. following its bankruptcy proceedings; the Company purchased Rendiatech primarily to gain access to such assets. The purchase expands Nuwellis' capabilities across the card

    3/17/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AZTR
    $LW
    $NUWE
    $PIRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer reiterated coverage on AT&T with a new price target

    Oppenheimer reiterated coverage of AT&T with a rating of Outperform and set a new price target of $32.00 from $29.00 previously

    3/11/26 7:56:43 AM ET
    $T
    Telecommunications Equipment
    Telecommunications

    AT&T upgraded by Arete with a new price target

    Arete upgraded AT&T from Sell to Neutral and set a new price target of $28.00

    3/10/26 8:36:07 AM ET
    $T
    Telecommunications Equipment
    Telecommunications

    AT&T downgraded by Arete with a new price target

    Arete downgraded AT&T from Neutral to Sell and set a new price target of $20.00

    1/6/26 8:44:42 AM ET
    $T
    Telecommunications Equipment
    Telecommunications

    $AZTR
    $LW
    $NUWE
    $PIRS
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AZTR
    $LW
    $NUWE
    $PIRS
    Financials

    Live finance-specific insights

    View All

    Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

    RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2025 financial results after the market closes on Monday, March 30, 2026. The company will hold a conference call at 4:30 p.m. Eastern on Monday, March 30, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participa

    3/19/26 4:03:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PROG Holdings, Inc. Investor Day Recap: Strategic Vision Outlined Including Selective Three-Year CAGR Financial Targets

    PROG Holdings, Inc. (NYSE:PRG), the fintech holding company for Progressive Leasing, Four Technologies, MoneyApp, and Purchasing Power, hosted its Investor Day in New York City on March 10, 2026. Members of the PROG leadership team outlined the Company's strategy to evolve from a leasing-centric business to a multi-product consumer access platform and shared consolidated three-year compound annual growth rates expected for select financial metrics. "Investor Day marked an important milestone in PROG's evolution," said Steve Michaels, President and Chief Executive Officer. "We are building a connected, multi-product platform designed to serve one core customer across a broader set of nee

    3/11/26 6:00:00 PM ET
    $PRG
    Diversified Commercial Services
    Consumer Discretionary

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AZTR
    $LW
    $NUWE
    $PIRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

    SC 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

    12/17/24 5:42:35 PM ET
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:56:51 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:18:21 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care